BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: San SN, Matsumoto J, Saito Y, Koike M, Sakaue H, Kato Y, Fujiyoshi M, Ariyoshi N, Yamada H. Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro. Xenobiotica 2019;49:935-44. [PMID: 30227770 DOI: 10.1080/00498254.2018.1524947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Niessen W. Tandem mass spectrometry of small-molecule antiviral drugs: 2. hepatitis-related antivirals. International Journal of Mass Spectrometry 2020;455:116371. [DOI: 10.1016/j.ijms.2020.116371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Matsumoto J, San SN, Fujiyoshi M, Kawauchi A, Chiba N, Tagai R, Sanbe R, Yanaka S, Sakaue H, Kato Y, Nakamura H, Yamada H, Ariyoshi N. Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir. J Hum Genet 2020;65:143-53. [PMID: 31645655 DOI: 10.1038/s10038-019-0685-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]